Annual reportMar 2026
Mar 2026 · Annual Report 2026
Source: Nse
Docmode Health Technologies Ltd. (DHTL)
SME CapPharma stocks · SME cap · NSE
Docmode Health Technologies Ltd. operates in HealthTech, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals16 Oct 2026 · screener
Latest result08 Sept, 12:42 am IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags24 Apr 2026
Coverage13/14 · 93%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
63BullishSMA20 -20.6% / mo · RSI oversold · MACD − · near 52W low · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 39
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
DHTLD candles · FIT view-54.0%Latest close ₹22.30 on 2026-10-14
Bar
+1.4%
RSI
28
MACD hist
-0.15
52W pos
0%
2026-10-14O ₹22.00H ₹22.30L ₹22.00C ₹22.30Vol 1,600 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
DHTLNifty PharmaNifty 500
- DHTL
- -42.2%
- Nifty 500
- -5.3%
- Nifty Pharma
- -1.1%
- Vs Nifty 500
- -36.9 pp
Chart stats
14 Oct 2026- From 52W high
- -82.2%
- 52W range position
- 0%
- ATR (14)
- 5.9%
- Volume vs 20D
- 0.06x
- Avg traded value
- ₹0.1 Cr
- 20D price channel
- ₹22 - ₹34.2
₹125.2
₹22 - ₹125.2
₹1.3
Latest completed session
20-session average
59.3% annualized volatility
Research snapshot
What the evidence says now
Weak fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is weak.
Suggested next step
Verify management risk first
Do not let cheap valuation override weak Trust or governance evidence.
U-Score
Legacy · OVERVALUED13
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Bad0
Revenue -53.2% · PAT NDF YoY
Technical
Bullish63
Price trend and sector-relative-strength timing.
Valuation
Legacy model—
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence44
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 31 Mar 2026
Bad · 0/100Rev -53% YoY · margin compression
Filed 31 Mar 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹7.7 Cr | -53.2% | -57.0% |
| EBITDA | ₹-1.2 Cr | NDF | -245.0% |
| Operating margin | -15.1% | NDF | -1960 bps |
| PAT | ₹-0.1 Cr | NDF | NDF |
| PAT margin | -0.9% | NDF | -41 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- —
- P/B
- 0.85
- EV/EBITDA
- —
- Market Cap
- 7.01Cr
Profitability
- ROE
- -1.57%
- ROCE
- 6.12%
- ROA
- -0.39%
- Dividend Y
- —
Growth (CAGR)
- Revenue 5Y
- 29.00%
- EPS 5Y
- 3.00%
- Revenue 3Y
- -8.00%
- EPS 3Y
- -8.00%
Balance Sheet
- Debt/Equity
- 0.45
- Interest Coverage
- -0.35×
- Altman Z
- 1.19
- Book Value
- 26.10
Cash Flow
- FCF Yield
- 34.38%
- FCF Positive Y
- 2/5
- OCF
- 4.30 Cr
- EPS TTM
- -0.41
Shareholding
- Promoter Hold
- 29.50%
- Promoter Pledge
- 37.40%
- Momentum 52W
- 0%
Financial History
Updated 19/10/2026
Revenue
₹ CrLatest: 25.4-39.1% vs prev
Net Profit
₹ CrLatest: -0.1+93.6% vs prev
Return on Equity
%Latest: -1.6+93.5% vs prev
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend unclear. RSI 28. Wait for confirmation.
- SMA20 falling (~25.9% over last month) — short-term momentum negative.
- RSI(14) at 28 — oversold zone; bounce conditions.
- MACD below signal but histogram contracting — bearish momentum easing.
- Within 5% of 52-week low — testing support.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
1
RS percentile
Stage 4 Downtrend
1M return
-28.9%
3M return
-44.2%
6M return
-80.1%
1Y return
-
RS 1D
0
RS 20D
0
Sector rank
#1
Industry rank
#17
Stage evidence
- Price is 63.6% below the 30-week proxy.
- The 50-DMA is below the 30-week proxy and its slope is falling -5.4%.
- Both 3-month and 6-month returns are negative.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
leading
Partial-history RS: the 3M and 6M weights are re-normalised because 12M history is unavailable.
Relative-strength line vs Nifty 500 (base 100)
149 observations
14 Oct 2026Value 33.72-1.00%
RS vs Nifty 50034
Valuation & peers
U-Score 13 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Valuation & peers
U-Score 13 · legacy U-Score band OVERVALUED · valuation evidence and comparable companies
Distress Watch
Fundamental score breakdown
U band · OVERVALUEDValuation5/30
Growth7/25
Quality0/20
Balance Sheet0/15
Cash Flow6/10
Piotroski
5/9 (+3)
Penalties
-8
Raw sum
13
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
13/100 · legacy band OVERVALUED
Positive drivers
- FCF yield is supportive at 34.4%.
- Cash flow contributes 6/10 to the score.
- Growth contributes 7/25 to the score.
Main drags
- Altman Z is 1.2, in distress territory.
- Promoter pledge is 37.4%.
- Penalty bucket subtracts 8 points.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
—
PB
0.8
EV/EBITDA
—
ROE
-1.6%
ROCE
6.1%
FCF Yield
34.4%
Debt/Equity
0.5
MoS
—
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
13
Previous: 13
Legacy U-Score band
OVERVALUED
Previous: OVERVALUED
Margin of safety
—
No stored baseline yet
Score history
12 stored score snapshots. Latest stored move: +0 points.
20 Oct 2026
v4.3-runtime-valuation
14
14
14
14
14
14
14
13
13
13
13
13
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
—
Growth-justified P/E
9.8
Growth-justified Value
—
— MoS
PEG
—
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
HEALTHX
Small
Health X Platform Limited
Healthcare Services
match 142
36
—
0.4%
—
WATCHLIST
MAXHEALTH
Large
Max Healthcare Institute Limited
Healthcare Services
match 124
35
67.5
12.7%
-497%
WATCHLIST
DENTALKART
SME
Vasa Denticity Ltd.
Healthcare Services
match 122
14
69.4
4.5%
-1604%
OVERVALUED
NEPHROCARE
SME
Nephro Care India Ltd.
Healthcare Services
match 122
14
27.7
4.9%
-464%
OVERVALUED
MAITREYA
SME
Maitreya Medicare Ltd.
Healthcare Services
match 122
12
—
-9.3%
—
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Docmode Health Technologies Ltd. operates in HealthTech, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 31 Mar 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
44Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 2nd percentile of the scored universe and 2nd percentile within Pharma. Main check: promoter alignment is weak at 17/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
0 docs text-extracted · 0 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
2nd percentile
overall median 67 · Pharma: 2nd pctile, median 70 · SME: 2nd pctile, median 64
Evidence depth
Financial-only
0 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Do not rely on management narrative unless hard turnaround evidence is visible.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
17
weak · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
55
watch · leverage and solvency
Discipline
30
weak · capital discipline
Results
31
weak · quarterly consistency
Trust positives
- ▸FCF yield is 23.6%.
Trust risks
- ▸Promoters have pledged 37.4% of holding.
- ▸Promoter holding fell 17.9%.
- ▸Altman Z is 1.27.
- ▸2 latest quarters had PAT decline worse than 25% YoY.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Docmode Health Technologies Ltd.
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Annual reportMar 2025
Mar 2025 · Annual Report 2025
Source: Nse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.